Company:  TESARO, INC. (TSRO)
Form Type:  10-Q
Filing Date:  7/27/2012 
CIK:  0001491576 
Address:  1000 WINTER STREET, SUITE 3300 
City, State, Zip:  WALTHAM, Massachusetts 02451 
Telephone:  (339) 970-0900 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$25.33  
Change: 
-0.04 (-0.16%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$911.63M
Description of Business
We are an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. We acquire, in-license and develop oncology product candidates and, if approved for marketing, we intend to commercialize these products globally. We have in-licensed and are currently developing three product candidates, rolapitant, niraparib and TSR-011, and in March 2014 we initiated our immuno-oncology platform strategy by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., or AnaptysBio, for the discovery and development of antibodies for specified immuno-oncology targets. � Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist currently in Phase 3 (oral formulation) and Phase 1 (intravenous, or IV, formulation) clinical trials for the prevention of chemotherapy induced nausea and vomiting, or CINV. In December 2013, we announced top-line results for two Phase 3 trials of rolapitant.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I FINANCIAL INFORMATION
      Item 1. Financial Statements.
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures.
    PART II OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 6. Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATIONS
  EXHIBIT 31.2
    CERTIFICATIONS
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS